Stress Ulcer ProphylaxisguidelineNCT06620263
Stress Ulcer Prophylaxis Practices in the Intensive Care Unit
An observational study of Stress Ulcer Prophylaxis, run by Yunus Emre AYHAN at 1 site in Turkey (Türkiye).
Trial summary
The present study aimed to examine the adherence of proton pump inhibitors (PPIs), commonly recommended for stress ulcer prevention (SUP) in patients in the intensive care unit (ICU), according to an international guideline. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stress Ulcer Prophylaxis
- What is being tested?
- Pre-education period (PreEd) and Post-education period (PostEd)
- How many people
- 495 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2024to 3 Jul 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This population includes ICU patients using PPI for SUP.
Who may be able to join
- Patients aged ≥18 years,
- ICU stay longer than 24 hours,
- PPI use for SUP
Who cannot join
- Patients with a diagnosis of gastric cancer
- Patients with a history of gastrointestinal issues
- Individuals who have undergone subtotal or total gastrectomy
- Those using proton pump inhibitors (PPIs) for treatment indications such as dual antiplatelet therapy
- Patients admitted to the intensive care unit (ICU) with gastrointestinal bleeding
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi
Istanbul, Turkey, 34444
About this study
Official title: Ensuring Guideline Adherence and Cost Savings in Stress Ulcer Prophylaxis Practices in the Intensive Care Unit: a Pre-Post Education Study
The present study aimed to examine the adherence of proton pump inhibitors (PPIs), commonly recommended for stress ulcer prevention (SUP) in patients in the intensive care unit (ICU), according to an international guideline. The objective of the study was to enhance the adherence of SUP prescriptions to the guideline, therefore preventing potential adverse effects and avoidable financial burden, and, consequently, attaining cost reduction.
Read the detailed description
Background Intensive care unit (ICU) patients are prone to developing stress-related gastrointestinal (GI) bleeding, which is associated with increased morbidity and mortality. Respiratory failure, hypotension, coagulopathy, and especially prolonged mechanical ventilation (MV) are the most critical clinically significant risk factors for GI bleeding in patients. Many studies have shown that invasive MV for 48 hours or longer and coagulopathy are two independent risk factors for clinically significant upper GI bleeding in ICU patients.
Stress ulcer prophylaxis (SUP) is widely practiced in ICUs worldwide and is often (up to 70%) used inappropriately. Proton pump inhibitors (PPI) are among the most commonly used medications in critically ill patients for SUP. However, the inappropriate and quite inconsistent use of PPIs in ICUs has added unnecessary costs, enhanced risks related to adverse drug reactions, and possible complications like pneumonia, Clostridium difficile infections, hypomagnesemia, and bone fractures.
A few studies have assessed adherence with SUP guidelines and institutional standards under the surveillance of a pharmacist. The results of these studies implied that pharmacist supervision reduced the inappropriate use of SUP in patients and its associated healthcare costs. One of these studies noted that the intervention and adjustment of pharmacists reduced the incidence of inappropriate use of SUP and its associated costs from $26.75 and $2433 per 100 patient days pre-intervention to $7.14 and $239.80 per 100 patient days post-intervention with p\<0.001. The same study emphasized that a comprehensive multidisciplinary approach must be implemented to decrease inappropriate SUP use in the ICU.
The aim of this study is to enhance adherence to the guidelines through an educational program focused on reducing inappropriate use of SUP in the ICU. The goal is to promote appropriate use of SUP based on indications, leading to cost savings.
Methods Study Design and Participants This study was designed as a non-randomized, controlled, prospective study created according to the pre-post education evaluation model. It was conducted in the anesthesia and reanimation ICU of a training and research hospital between January 2024 and July 2024 (6 months). The study was conducted in pre-education (PreEd) and post-education (PostEd). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024). In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed. Throughout the study period, the appropriateness of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline].
Education Program The education program was organized on April 3, 2024, after completing the 3-month PreEd review. The 1-hour education program was presented face-to-face to ICU physicians by a clinical pharmacist and an intensive care specialist physician. The content of the education included education on SUP, pathophysiology of stress ulcer, SUP risk/benefit situations, guidelines for SUP, introduction of appropriate SUP criteria according to the SPC SUP guideline, and frequently inappropriate SUP prescription situations in ICU, and the correct time to stop SUP. The evaluations obtained during the PreEd review in the ICU were also presented to the physicians participating in the education.
Data Collection Sociodemographic information, disease and medication history, existing laboratory values (coagulation parameters, procalcitonin, c-reactive protein, etc.), culture results, MV status, nutritional status, GI system bleeding status, pneumonia status, presence of Clostiridioides difficile, appropriate/inappropriate SUP use days and costs were obtained from the patient\'s treatment file and the hospital information management system with the utmost respect for personal privacy conditions.
Assessment of the Stress Ulcer Prophylaxis Use SUP use of ICU patients was evaluated throughout the week. SUP practices of ICU patients and patient data were reviewed by a clinical pharmacist and an intensive care specialist and evaluated for compliance with the SPC SUP criteria in terms of indication [12]. No intervention was made in the patients\' SUP practices in either period.
Sample Size For the study\'s sample size, it was determined that there should be at least 42 patients in each period, based on the literature data that inappropriate SUP use in patient groups is reduced by approximately 30%, based on the calculation made on alpha 0.05 and 95% power values. Considering the 15% loss margin, it was decided to include 96 patients in the study, with at least 48 patients each period.
Definitions Authors defined significant GI bleeding as bleeding requiring a gastroscopy or blood transfusion upon clinician judgment. C. difficile infection was defined as the presence of relevant symptoms with positive fecal toxin and/or polymerase chain reaction in ICU patients after initiation of SUP in the ICU.
The rate of SUP use in appropriate indications was accepted as the percentage of PPIs used by a patient according to the SPC SUP guideline for the total number of hospital days.
Outcomes Measurement Adherence rates to SPC SUP guideline and costs of nonadherence were primary outcome measurements.
Inclusion and Exclusion Criteria Patients aged ≥18 years, those with an ICU stay longer than 24 hours, and those using PPIs for SUP were included in the study. Patients with a diagnosis of gastric cancer, history of GI, those with subtotal/total gastrectomy, those using PPIs for treatment indications such as dual antiplatelet therapy, and those admitted to the ICU with GI bleeding were excluded from the study.
Statistical analysis The study used descriptive statistics including mean, median, standard deviation, interquartile range (IQR), count, and percentages to show continuous variables' central tendency and variability. For categorical variables, frequency, and percentages were given. The Kolmogorov-Smirnov test was used to see if continuous variables followed the normal distribution. The result was non-parametric. The Mann-Whitney U tests were used to compare continuous variables between two groups. Categorical data was compared using Chi-square tests. A 95% confidence interval (CI) with a p-value less than 0.05 was considered statistically significant. Analysis of the dataset was done on an overall basis with the help of IBM SPSS Statistics for Windows, Version 29.0 (Armonk, New York: IBM Corp.), Cost Savings Analysis This study compared the costs of SUP agents prescribed for inappropriate indications between PreEd and PostEd. Finally, the SUP cost per patient was determined by multiplying the number of appropriate and inappropriate days of use in both PreEd and PostEd by the cost of PPI. Differences in the SUP costs between PreEd and PostEd are called cost-saving.
The costs for the SUP agents were estimated using current drug prices available from the hospital where this study was conducted. Thus, ten pantoprazole intravenous (IV) ampules were accepted for $3. Only the costs related to PPIs have been calculated. The calculation excluded nursing services and medical supplies.
- Conditions
- Stress Ulcer Prophylaxis
- Being tested
- Pre-education period (PreEd), Post-education period (PostEd)
- Keywords
- Stress ulcer prophylaxis, Proton pump inhibitor, Intensive care unit, Clinical pharmacist
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pre-education period (PreEd)Other
No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).
Post-education period (PostEd)Other
In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
| Study group | Role | What they receive |
|---|---|---|
| Pre-education period (PreEd) | In PreEd, the SUP use of patients in the ICU was observed observationally for three months. Receives: Other: Pre-education period (PreEd) | |
| Post-education period (PostEd) | The SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed. Throughout the study period, the appropriateness of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline Receives: Other: Post-education period (PostEd) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stress ulcer prophylaxis appropriate rate
The appropriateness rates of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline. Accordingly, the adherence rate was calculated by dividing the SUP prescriptions in accordance with the guideline during a patient\'s hospitalization by the SUP use during the entire hospitalization.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start1 Jan 2024
- Primary completion3 Jul 2024
- Study completion3 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Stress Ulcer ProphylaxisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 495 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yunus Emre AYHAN
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Yunus Emre AYHAN, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06620263
- Sponsor's protocol ID
- 249/20.11.2023
- Acronym
- guideline
- Status last verified
- Sep 2024
- First submitted
- 24 Sep 2024
- Last updated
- 1 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: I do not have a legal right to share IPD in the country I am in. Therefore, I cannot share IPD.
Publications
Mendes JJ, Silva MJ, Miguel LS, Goncalves MA, Oliveira MJ, Oliveira CDL, Gouveia J. Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit. Rev Bras Ter Intensiva. 2019;31(1):5-14. doi: 10.5935/0103-507X.20190002. Epub 2019 Feb 28.
PubMed 30843949
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ensuring Guideline Adherence and Cost Savings in Stress Ulcer Prophylaxis Practices in the Intensive Care Unit: a Pre-Post Education Study
- ClinicalTrials.gov ID
- NCT06620263
- Acronym / sponsor ID
- guideline / 249/20.11.2023
- Conditions
- Stress Ulcer Prophylaxis
- Keywords
- Stress ulcer prophylaxis, Proton pump inhibitor, Intensive care unit, Clinical pharmacist
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 495 participants (actual)
- Lead sponsor
- Yunus Emre AYHANUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 3 Jul 2024 (actual)
- Study completion
- 3 Jul 2024 (actual)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study aimed to examine the adherence of proton pump inhibitors (PPIs), commonly recommended for stress ulcer prevention (SUP) in patients in the intensive care unit (ICU), according to an international guideline. The objective of the study was to enhance the adherence of SUP prescriptions to the guideline, therefore preventing potential adverse effects and avoidable financial burden, and, consequently, attaining cost reduction.
Detailed description
Background Intensive care unit (ICU) patients are prone to developing stress-related gastrointestinal (GI) bleeding, which is associated with increased morbidity and mortality. Respiratory failure, hypotension, coagulopathy, and especially prolonged mechanical ventilation (MV) are the most critical clinically significant risk factors for GI bleeding in patients. Many studies have shown that invasive MV for 48 hours or longer and coagulopathy are two independent risk factors for clinically significant upper GI bleeding in ICU patients.
Stress ulcer prophylaxis (SUP) is widely practiced in ICUs worldwide and is often (up to 70%) used inappropriately. Proton pump inhibitors (PPI) are among the most commonly used medications in critically ill patients for SUP. However, the inappropriate and quite inconsistent use of PPIs in ICUs has added unnecessary costs, enhanced risks related to adverse drug reactions, and possible complications like pneumonia, Clostridium difficile infections, hypomagnesemia, and bone fractures.
A few studies have assessed adherence with SUP guidelines and institutional standards under the surveillance of a pharmacist. The results of these studies implied that pharmacist supervision reduced the inappropriate use of SUP in patients and its associated healthcare costs. One of these studies noted that the intervention and adjustment of pharmacists reduced the incidence of inappropriate use of SUP and its associated costs from $26.75 and $2433 per 100 patient days pre-intervention to $7.14 and $239.80 per 100 patient days post-intervention with p\<0.001. The same study emphasized that a comprehensive multidisciplinary approach must be implemented to decrease inappropriate SUP use in the ICU.
The aim of this study is to enhance adherence to the guidelines through an educational program focused on reducing inappropriate use of SUP in the ICU. The goal is to promote appropriate use of SUP based on indications, leading to cost savings.
Methods Study Design and Participants This study was designed as a non-randomized, controlled, prospective study created according to the pre-post education evaluation model. It was conducted in the anesthesia and reanimation ICU of a training and research hospital between January 2024 and July 2024 (6 months). The study was conducted in pre-education (PreEd) and post-education (PostEd). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024). In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed. Throughout the study period, the appropriateness of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline].
Education Program The education program was organized on April 3, 2024, after completing the 3-month PreEd review. The 1-hour education program was presented face-to-face to ICU physicians by a clinical pharmacist and an intensive care specialist physician. The content of the education included education on SUP, pathophysiology of stress ulcer, SUP risk/benefit situations, guidelines for SUP, introduction of appropriate SUP criteria according to the SPC SUP guideline, and frequently inappropriate SUP prescription situations in ICU, and the correct time to stop SUP. The evaluations obtained during the PreEd review in the ICU were also presented to the physicians participating in the education.
Data Collection Sociodemographic information, disease and medication history, existing laboratory values (coagulation parameters, procalcitonin, c-reactive protein, etc.), culture results, MV status, nutritional status, GI system bleeding status, pneumonia status, presence of Clostiridioides difficile, appropriate/inappropriate SUP use days and costs were obtained from the patient\'s treatment file and the hospital information management system with the utmost respect for personal privacy conditions.
Assessment of the Stress Ulcer Prophylaxis Use SUP use of ICU patients was evaluated throughout the week. SUP practices of ICU patients and patient data were reviewed by a clinical pharmacist and an intensive care specialist and evaluated for compliance with the SPC SUP criteria in terms of indication [12]. No intervention was made in the patients\' SUP practices in either period.
Sample Size For the study\'s sample size, it was determined that there should be at least 42 patients in each period, based on the literature data that inappropriate SUP use in patient groups is reduced by approximately 30%, based on the calculation made on alpha 0.05 and 95% power values. Considering the 15% loss margin, it was decided to include 96 patients in the study, with at least 48 patients each period.
Definitions Authors defined significant GI bleeding as bleeding requiring a gastroscopy or blood transfusion upon clinician judgment. C. difficile infection was defined as the presence of relevant symptoms with positive fecal toxin and/or polymerase chain reaction in ICU patients after initiation of SUP in the ICU.
The rate of SUP use in appropriate indications was accepted as the percentage of PPIs used by a patient according to the SPC SUP guideline for the total number of hospital days.
Outcomes Measurement Adherence rates to SPC SUP guideline and costs of nonadherence were primary outcome measurements.
Inclusion and Exclusion Criteria Patients aged ≥18 years, those with an ICU stay longer than 24 hours, and those using PPIs for SUP were included in the study. Patients with a diagnosis of gastric cancer, history of GI, those with subtotal/total gastrectomy, those using PPIs for treatment indications such as dual antiplatelet therapy, and those admitted to the ICU with GI bleeding were excluded from the study.
Statistical analysis The study used descriptive statistics including mean, median, standard deviation, interquartile range (IQR), count, and percentages to show continuous variables' central tendency and variability. For categorical variables, frequency, and percentages were given. The Kolmogorov-Smirnov test was used to see if continuous variables followed the normal distribution. The result was non-parametric. The Mann-Whitney U tests were used to compare continuous variables between two groups. Categorical data was compared using Chi-square tests. A 95% confidence interval (CI) with a p-value less than 0.05 was considered statistically significant. Analysis of the dataset was done on an overall basis with the help of IBM SPSS Statistics for Windows, Version 29.0 (Armonk, New York: IBM Corp.), Cost Savings Analysis This study compared the costs of SUP agents prescribed for inappropriate indications between PreEd and PostEd. Finally, the SUP cost per patient was determined by multiplying the number of appropriate and inappropriate days of use in both PreEd and PostEd by the cost of PPI. Differences in the SUP costs between PreEd and PostEd are called cost-saving.
The costs for the SUP agents were estimated using current drug prices available from the hospital where this study was conducted. Thus, ten pantoprazole intravenous (IV) ampules were accepted for $3. Only the costs related to PPIs have been calculated. The calculation excluded nursing services and medical supplies.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pre-education period (PreEd) | – | Other: Pre-education period (PreEd)In PreEd, the SUP use of patients in the ICU was observed observationally for three months. |
| Post-education period (PostEd) | – | Other: Post-education period (PostEd)The SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed. Throughout the study period, the appropriateness of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This population includes ICU patients using PPI for SUP.
Key inclusion criteria (3 listed)
- Patients aged ≥18 years,
- ICU stay longer than 24 hours,
- PPI use for SUP
Key exclusion criteria (5 listed)
- Patients with a diagnosis of gastric cancer
- Patients with a history of gastrointestinal issues
- Individuals who have undergone subtotal or total gastrectomy
- Those using proton pump inhibitors (PPIs) for treatment indications such as dual antiplatelet therapy
- Patients admitted to the intensive care unit (ICU) with gastrointestinal bleeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pre-education period (PreEd)No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024). | Other | Pre-education period (PreEd) |
| Post-education period (PostEd)In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed. | Other | Post-education period (PostEd) |
Primary outcome
Stress ulcer prophylaxis appropriate rate
Time frame: through study completion, an average of 1 year
The appropriateness rates of SUP uses for the indication was evaluated according to the Sociedade Portuguesa de Cuidados (SPC) SUP guideline. Accordingly, the adherence rate was calculated by dividing the SUP prescriptions in accordance with the guideline during a patient\'s hospitalization by the SUP use during the entire hospitalization.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2024.
- Background: PubMed 30843949Mendes JJ, Silva MJ, Miguel LS, Goncalves MA, Oliveira MJ, Oliveira CDL, Gouveia J. Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit. Rev Bras Ter Intensiva. 2019;31(1):5-14. doi: 10.5935/0103-507X.20190002. Epub 2019 Feb 28.
- In this study, the guideline is the reference taken as the source for adherence.Link provided by the sponsor.
- Individual participant dataSharing planned: No. I do not have a legal right to share IPD in the country I am in. Therefore, I cannot share IPD.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stress Ulcer Prophylaxis, run by Yunus Emre AYHAN at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stress ulcer prophylaxis appropriate rate (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06620263, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2024.